Know Cancer

or
forgot password

The Use of Helical Tomotherapy to Achieve Dose-per-fraction Escalation in Lung Cancer


Phase 1
18 Years
N/A
Not Enrolling
Both
Lung Cancer

Thank you

Trial Information

The Use of Helical Tomotherapy to Achieve Dose-per-fraction Escalation in Lung Cancer


Inclusion Criteria:



- Thoracic neoplasm requiring at lest 60 Gy conventional radiotherapy

Exclusion Criteria:

- Prior bleomycin or gemcitabine chemotherapy

- Prior thoracic radiotherapy

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

Grade 3 pneumonitis lasting greater than 2 weeks

Outcome Time Frame:

90 days post radiotherapy (XRT)

Safety Issue:

Yes

Principal Investigator

Anne Traynor, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Wisconsin, Madison

Authority:

United States: Institutional Review Board

Study ID:

RO04502

NCT ID:

NCT00214123

Start Date:

June 2004

Completion Date:

December 2012

Related Keywords:

  • Lung Cancer
  • Lung Neoplasms

Name

Location

University of Wisconsin Hospital and ClinicsMadison, Wisconsin  53792-0001